Spondyloarthropathies (SpA) are often diagnosed with a considerable delay (often 8-10 years from symptom onset), because the available clinical, biochemical and radiological methods are not sufficiently sensitive. TNF-a antagonists have recently been introduced for treatment of SpA, and current data indicate a higher efficacy than previously available therapies. The improved treatment options have increased the need for improved methods for diagnosis, monitoring and prognostication of these diseases, so that the efficient therapies can be initiated at the optimal time point and monitored optimally. Magnetic resonance imaging (MRI) and a number of biomarkers are promising, but not yet sufficiently studied, methods for this.
See brief summary
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
52
sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
Department of Radiology, Aabenraa Hospital
Aabenraa, Denmark
Department of Radiology, Århus University Hospital
Aarhus, Denmark
Department of Radiology, Herlev University Hospital
Copenhagen, Denmark
Department of Rheumatology, Bispebjerg University Hospital
Copenhagen, Denmark
Department of Rheumatology, Gentofte University Hospital
Copenhagen, Denmark
Department of Rheumatology, Glostrup University Hospital
Copenhagen, Denmark
Department of Rheumatology, Herlev University Hospital
Copenhagen, Denmark
Department of Rheumatology, Hvidovre University Hospital
Copenhagen, Denmark
King Christian X´s Hospital of Rheumatic Diseases
Gråsten, Denmark
Department of Rheumatology, Hørsholm Hospital
Hørsholm, Denmark
...and 3 more locations
Reduction in BASDAI of 20 mm or 50%
Time frame: 12-24 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.